Combined use of cetuximab and chemotherapy in recurrent or metastatic squamous cell carcinoma of head and neck / 国际肿瘤学杂志

ABSTRACT

Recurrent or metastatic squamous cell carcinoma of the head and neck(SCCHN) has a poor prognosis. Cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptor (EGFR) and improves the effect of several chemotherapeutical agents including cisplatin. Several clinical trials have shown that cetuximab combined with chemotherapy was effective and well tolerated for the treatment of recurrent or metastatic SCCHN. The strengths of such treatment are its high efficacy and low toxicity.